-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

584 Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL
Hematology Disease Topics & Pathways:
Combination therapy, Therapy sequence, Treatment Considerations, Measurable Residual Disease
Sunday, December 8, 2024: 12:15 PM

Anne Sophie Michallet, MD, PhD1,2*, Remi Letestu3*, Magali Legarff4*, Stéphane Morisset5*, Therese Aurran-Schleinitz, MD6*, Kamel Laribi7*, Vincent Levy, MD, PhD8*, Laurence Simon9*, Damien Roos Weil, MD10*, Marie Sarah Dilhuydy, MD11*, Cecile Tomowiak, MD12*, Caroline Dartigeas, MD13*, Romain Guieze, MD, PhD14*, Olivier Tournilhac15*, Emmanuelle Ferrant16*, Sophie De Guibert17*, Pierre Feugier, MD, PhD18*, Fatiha Merabet, MD19*, Stéphane Lepretre20*, Philippe Carassou21*, Julie Gay22*, Benedicte Hivert23*, Luc-Matthieu Fornecker, MD, PhD24*, Jehan Dupuis, MD25*, Lysiane Molina, MD26*, Bruno Villemagne, MD27*, Guillaume Cartron, MD, PhD28*, Bernard Drenou, MD29*, Omar Benbrahim, MD30*, Xavier Cahu31*, Florence Nguyen Khac32*, Valerie Rouillé33*, Loic Ysebaert, MD, PhD34* and Anne Quinquenel35*

1Hematology department, Robert Debré University Hospital, Reims, France
2UFR Médecine, Université Reims Champagne-Ardenne, Reims, France
3avicennes hospital, Avicennes, France
4APHP La pitié salpetriere, Paris, France
5Centre Léon Bérard, Fi-LMC, Lyon, France
6IPC, marseille, France
7CH Le Mans, Le mans, France
8Centre de Recherche Clinique, Hôpital Avicenne, AP-HP et Université Sorbonne, Paris, France
9hospital Corbeil essonnes, Corbeil-Essonnes, FRA
10Clinical Hematology, APHP, La Pitié Salpétriere, Sorbonne Universite, Paris, FRA
11CHU Bordeaux, PESSAC, FRA
12Hematology department & CIC 1402, Poitiers University Hospital, Poitiers, France
13CHU Bretonneau, Tours, FRA
14CHU Estaing, Clermont Ferrand, FRA
15CHU Estaing, Clermont-Ferrand University Hospital, CLERMONT FERRAND, AURA, France
16Department of Hematology, Lyon Sud Hospital, Pierre Benite, France
17Centre Hospitalier Pontchaillou, Rennes, FRA
18CHU Brabois - Service d'Hématologie - Université Henri Poincaré, Nancy, France
19andre mignot hospital, LE CHESNAY, FRA
20centre henri becquerel, Rouen, FRA
21Centre Hospitalier Regional Metz-Thionville, Hopital Mercy, Metz, France
22CH Côte basque, Bayonne, FRA
23GHICL, Lille, FRA
24Institut De Cancérologie Strasbourg Europe, Hematology Department, Strasbourg, France
25APHP, Creteil, Creteil, FRA
26CHU grenoble, grenoble, France
27CH la roche sur yon, La Roche Sur Yon, FRA
28Centre Hospitalier Universitaire de Montpellier, Montpellier, France
29Laboratoire d'Hématologie, Groupe Hospitalier de la Région Mulhouse Sud Alsace, Mulhouse, France
30HOPITAL LA SOURCE, La Source, FRA
31hospital cesson sevigne, cesson sevigne, France
32Hôpital Pitié-Salpêtrière, Service d'Hématologie, Paris, France
33CHU montpellier, montpellier, France
34Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
35CHU reims, reims, France

With the emergence of targeted therapies, defining the best strategy for first-line treatment in patients with chronic lymphocytic leukemia (CLL) has become challenging. The aim of the ERADIC phase 2 trial (NCT04010968) was to compare the efficacy of a standard fludarabine-cyclophosphamide-rituximab (FCR) regimen to that of a combination of ibrutinib and venetoclax (IV), guided by measureable residual disease (MRD), in fit patients with CLL of intermediate risk defined by either unmutated IGHV status, del(11q) or complex karyotype in the absence of TP53 alteration. MRD was assessed in bone marrow (BM) or peripheral blood (PB) by flow cytometry. After a lead-in phase of ibrutinib as a single agent from month (M)1 to M3, the total duration of treatment with the IV combination was based on M9 BM-MRD. If it was <0.01% (uMRD) at that time, treatment was continued for 6 additional months (M15) then stopped. If M9 BM-MRD was ≥0.01%, IV treatment was continued for 18 additional months (M27). BM-MRD was reassessed at that time-point in both arms. Additionally, PB-MRD evaluation was performed every 6 months.The primary endpoint was the percentage of patients with BM uMRD at M27. Here, the final results of the study are presented.

Between September 2019 and February 2021, 120 patients were randomized 1:1 between the 2 treatment arms. Their median age was respectively of 59 [34-72] and 61 [34-74] years in the FCR and IV arms. Patient characteristics were well balanced between the 2 arms in terms of gender (male 72% FCR, 74% IV), PS ECOG 0-1 (59% FCR, 68% IV) and Binet stage (A, B and C 15%, 64%, 21% for FCR ; 8.5%, 59% and 32% for IV). A del(11q) was found in respectively 20% and 24% patients in FCR and IV arms, and all patients but one had unmutated IGHV.

With a median follow-up of 42 months [range: 38– 46], 36 serious adverse events occurred in the FCR arm and 34 in the IV arm. Toxicities differed between the 2 arms with more infections and hematological toxicities due to myelosuppression (22%) and infections (40%) in the FCR arm, versus more cardiological events (23%), metabolic disorders (16%) and infections (27%) in the IV arm. Six grade 5 adverse events were reported, respectively 3 in the FCR arm (1 septic shock [M21], 1 acute myeloid leukemia [AML; M13] and 1 myelodysplastic syndrome [MDS; M24]) and 3 in the IV arm (2 sudden deaths [M7 and M12] and one COVID-19-related death at M27). In terms of secondary malignancies, in the FCR arm, squamous cell cancer, MDS, AML, colon cancer, basal cell carcinoma and lung cancer were reported while in the IV arm, liver, invasive skin, prostate, and squamous cell scalp cancers were observed as well as a bronchial carcinoma.

Treatment reduction and/or discontinuation involved 11 patients due to cardiac events (ibrutinib) and grade 4 neutropenia (venetoclax).

In terms of response (M27), complete response (CR) or CR with incomplete count recovery (CRi) rates were 53% for the FCR arm and 68% for the IV arm (p=0.097).Assessment of MRD in PB showed a statistically significant difference with 67% of PB uMRD for the FCR arm vs. 83% for the IV arm (p=0.056). BM uMRD rates were respectively of 54% and 68%, yet without reaching statistical significance.

Superiority for the IV arm was bserved in 3-year progression-free survival (PFS) at 78.5% for the FCR arm and 93% for the IV arm (p=0.029), yet without difference in overall survival (95% for both arms).

In conclusion, these final results confirm the superiority of the fixed and maximal duration of 27 months IV combination over chemotherapy, resulting in a very high PB uMRD rate and excellent 3-year PFS. Vigilance remains regarding cardiological toxicity which requires defining the best patient profile for this combination.

Disclosures: Roos Weil: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly/Loxo: Consultancy. Ferrant: Astra Zeneca, BeiGene, Janssen: Consultancy; Astra Zeneca, BeiGene, Janssen, Cilag, AbbVie, Gilead: Honoraria. Gay: Sanofi: Consultancy; Janssen: Consultancy; Amgen: Consultancy; Pfizer: Consultancy; Beigene: Consultancy. Cartron: Abbvie: Consultancy, Honoraria; Gilead: Honoraria; Ownards therapeutics: Consultancy; BMS: Consultancy, Honoraria; Roche, BMS, Gilead, Novartis, Takeda, Beigen, Janssen, AbbVie: Honoraria; Roche, BMS, AbbVie, Ownards therapeutics, MAbQi, MedXcell, BeiGene: Consultancy; Novartis: Honoraria; MAbQi: Consultancy; Takeda: Honoraria; MedXcell: Consultancy; Beigene: Consultancy, Honoraria; Janssen: Honoraria; Roche: Consultancy, Honoraria. Drenou: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees. Ysebaert: AbbVie, AstraZeneca, Janssen, Roche, Beigene, BMS/Celgene, Gilead/Kite: Membership on an entity's Board of Directors or advisory committees, Research Funding.

*signifies non-member of ASH